# Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only

> **NCT06721585** · — · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 328 (actual)

## Conditions studied

- Mpox (Monkeypox)

## Interventions

- **DRUG:** Tecovirimat Oral Capsule [Tpoxx]
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT06721585
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-10
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721585, "Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06721585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*